Literature DB >> 24727449

DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers.

Ki Hyung Kim1, Yun-Jeong Kang2, Jin-Ok Jo2, Mee Sun Ock2, Soo Hyun Moon1, Dong Soo Suh1, Man Soo Yoon1, Eun-Sil Park3, Namkung Jeong4, Wan-Kyu Eo5, Heung Yeol Kim6, Hee-Jae Cha7.   

Abstract

DDX4 (DEAD box polypeptide 4), characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), is an RNA helicase which is implicated in various cellular processes involving the alteration of RNA secondary structure, such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly. DDX4 is known to be a germ cell-specific protein and is used as a sorting marker of germline stem cells for the production of oocytes. A recent report about DDX4 in ovarian cancer showed that DDX4 is overexpressed in epithelial ovarian cancer and disrupts a DNA damage-induced G2 checkpoint. We investigated the relationship between DDX4 and ovarian cancer stem cells by analyzing the expression patterns of DDX4 and the cancer stem cell marker CD133 in ovarian cancers via tissue microarray. Both DDX4 and CD133 were significantly increased in ovarian cancer compared to benign tumors, and showed similar patterns of expression. In addition, DDX4 and CD133 were mostly colocalized in various types of ovarian cancer tissues. Furthermore, almost all CD133 positive ovarian cancer cells also express DDX4 whereas CD133-negative cells did not possess DDX4, suggesting a strong possibility that DDX4 plays an important role in cancer stem cells, and/or can be used as an ovarian cancer stem cell marker.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD133; Cancer stem cells; DDX4; Ovarian cancer

Mesh:

Substances:

Year:  2014        PMID: 24727449     DOI: 10.1016/j.bbrc.2014.03.144

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  Chemotherapy targeting cancer stem cells.

Authors:  Haiguang Liu; Lin Lv; Kai Yang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 2.  Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis.

Authors:  Quan Zhou; Aihua Chen; Huamei Song; Jing Tao; Huaijie Yang; Manzhen Zuo
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 3.  An unregulated regulator: Vasa expression in the development of somatic cells and in tumorigenesis.

Authors:  Jessica Poon; Gary M Wessel; Mamiko Yajima
Journal:  Dev Biol       Date:  2016-05-11       Impact factor: 3.582

Review 4.  Ovarian stem cells: From basic to clinical applications.

Authors:  Ozlem Bingol Ozakpinar; Anne-Marie Maurer; Derya Ozsavci
Journal:  World J Stem Cells       Date:  2015-05-26       Impact factor: 5.326

5.  Ovarian Cancer Stem Cells: Unraveling a Germline Connection.

Authors:  Seema C Parte; Andrei Smolenkov; Surinder K Batra; Mariusz Z Ratajczak; Sham S Kakar
Journal:  Stem Cells Dev       Date:  2017-11-28       Impact factor: 3.272

6.  Germline factor DDX4 functions in blood-derived cancer cell phenotypes.

Authors:  Natalie Schudrowitz; Satoshi Takagi; Gary M Wessel; Mamiko Yajima
Journal:  Cancer Sci       Date:  2017-07-11       Impact factor: 6.716

7.  Subsite-specific association of DEAD box RNA helicase DDX60 with the development and prognosis of oral squamous cell carcinoma.

Authors:  Ting-Ying Fu; Chao-Nan Wu; Huei-Cin Sie; Jiin-Tsuey Cheng; Yaoh-Shiang Lin; Huei-Han Liou; Yu-Kai Tseng; Chih-Wen Shu; Kuo-Wang Tsai; Leing-Ming Yen; Hui-Wen Tseng; Ching-Jiunn Tseng; Luo-Ping Ger; Pei-Feng Liu
Journal:  Oncotarget       Date:  2016-12-20

8.  Identification of germ cell-specific VASA and IFITM3 proteins in human ovarian endometriosis.

Authors:  Nicolas A Fraunhoffer; Analía Meilerman Abuelafia; Inés Stella; Silvia Galliano; Marcela Barrios; Alfredo D Vitullo
Journal:  J Ovarian Res       Date:  2015-10-07       Impact factor: 4.234

Review 9.  Cancer stem cells (CSCs), cervical CSCs and targeted therapies.

Authors:  Ruixia Huang; Einar K Rofstad
Journal:  Oncotarget       Date:  2017-05-23

10.  Abnormal gametogenesis induced by p53 deficiency promotes tumor progression and drug resistance.

Authors:  Chunfang Liu; Zhen Cai; Guoxiang Jin; Danni Peng; Bo-Syong Pan; Xian Zhang; Fei Han; Xiaohong Xu; Hui-Kuan Lin
Journal:  Cell Discov       Date:  2018-10-02       Impact factor: 10.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.